2 stories mentioning HKG:1349Updated just now
Every FINWIRES story that references HKG:1349, newest first.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) recorded a 546% surge in profit attributable to shareholders in the first half to 36.9 million yuan from 5.7 million yuan a year prior.Earnings per share increased to 0.0355 yuan from 0.0055 yuan previously, according to a Friday Hong Kong bourse filing.Revenue slipped 4.6% to 372.2 million yuan from 390.1 million yuan a year prior.
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical (HKG:1349, SHA:688505) posted net profit attributable to shareholders of 7.7 million yuan for the first quarter, up 189% from 2.7 million yuan a year earlier, according to a Wednesday Hong Kong bourse filing.Hong Kong-listed shares of the biotech firm were up nearly 2% in recent trade.Earnings per share came in at 0.01 yuan, compared with a near-zero figure a year earlier.Revenue fell 17% to 149.1 million yuan from 179.9 million yuan in the prior-year period.
